Vertex Pharmaceuticals (VRTX -4.3%)
says the COVID-19 outbreak has not negatively impacted its supply chain
or 2020 outlook, adding that has safety stock to account for potential
disruptions and has secured second-source suppliers in a range of
geographies.
2020 guidance issued on January 30: Product sales: $5.1B – 5.3B.
https://seekingalpha.com/news/3549787-vertex-backs-2020-forecast
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.